Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and...

Related Keywords

United States ,Texas ,London ,City Of ,United Kingdom ,Manchester ,Alabama ,Claremont ,Surrey ,American ,Frank Sciurba ,Mark Dransfield ,Donald Mahler ,Antonio Anzueto ,Ravi Kalhan ,Verona Pharma ,Nathan Marchetti ,Dave Singh ,Leslie Humbel ,Northwestern University ,University Of Pittsburgh Medical Center ,Lewis Katz School Of Medicine ,American Thoracic Society International Conference ,Temple University ,Nasdaq ,Bridge Communications ,University Of Pittsburgh School Medicine ,Globenewswire Inc ,International Us Media Enquiries ,University Of Manchester ,Drug Administration ,Action Date ,Thoracic Society International Conference ,Late Breaking Mini Symposium ,Critical Care ,Associate Professor ,Pittsburgh School ,Breaking Mini Symposium ,Ensifentrine Reduces Exacerbation Frequency ,Delays Progression ,Pittsburgh Medical ,Late Breaking Abstracts ,Improved Lung Function ,Reduced Exacerbations ,Symptomatic Subjects ,Alabama Birmingham ,Selective Inhibitor ,Severe Exacerbation Rate ,Subjects With ,Baseline Blood ,Ensifentrine Added ,Symptomatic Subjects With Moderate To Severe ,Thoracic Medicine ,Katz School ,Life Reported With Ensifentrine ,Pooled Analysis ,Respiratory Pharmacology ,Subjects With Symptomatic Moderate To Severe ,Improved Dyspnea ,Subjects With Symptomatic ,Regional Hospital ,Reduced Dyspnea ,Improved Quality ,Pulmonary Critical Care ,Kingdom Tel ,Senior Director ,Investor Relations ,Annual Report ,Quarterly Reports ,